Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome (II) plus ivoximab as second-line therapy for extensive-stage small cell lung cancer
ChiCTR2500101869Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Apr 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan and ivonescimab in small cell lung cancer (SCLC), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Progression-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
irinotecanivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500101869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101869.